Neumora Discontinues Depression Drug After Phase 3 Failure, Cuts 35% Workforce, Extends Cash Runway
NMRA has more than doubled off its 52-week low of $0.716.
Summary
Neumora Therapeutics is discontinuing its lead depression drug after Phase 3 failure, leading to a 35% workforce reduction and an extended cash runway into Q3 2027.
Key Events · Product Development and Regulatory · NMRA
-
Phase 3 Drug Discontinuation
The company is discontinuing the development of navacaprant for Major Depressive Disorder after its Phase 3 KOASTAL-2 and -3 studies failed to achieve statistical significance on primary or key secondary endpoints.
-
Significant Workforce Reduction
A reduction in force of approximately 35% was implemented, expected to result in annualized cost savings of $10 million, partially offset by $2 million in one-time restructuring costs.
-
Extended Cash Runway
Following the workforce reduction, the company now expects its cash and cash equivalents to provide runway into the third quarter of 2027, an extension from previous estimates.
-
Loan Agreement Amended
The company amended its loan agreement, extending the interest-only period and modifying minimum liquidity covenants, providing greater financial flexibility.
Analysis · NMRA · Life Sciences
Neumora Therapeutics announced the discontinuation of its lead depression drug, navacaprant, after it failed to meet primary endpoints in two Phase 3 studies. This major pipeline setback led to a 35% workforce reduction, which is expected to generate $10 million in annual cost savings. These measures, combined with an amended loan agreement, extend the company's cash runway into the third quarter of 2027, providing critical time for its remaining pipeline programs.
At the time of this filing, NMRA was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $329.8M. The 52-week trading range was $0.72 to $3.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.